|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
3
|
Kumar M, Zhao X and Wang XW: Molecular
carcinogenesis of hepatocellular carcinoma and intrahepatic
cholangiocarcinoma: One step closer to personalized medicine? Cell
Biosci. 1:52011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brown KS: Chemotherapy and other systemic
therapies for hepatocellular carcinoma and liver metastases. Semin
Intervent Radiol. 23:99–108. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cao H, Phan H and Yang LX: Improved
chemotherapy for hepatocellular carcinoma. Anticancer Res.
32:1379–1386. 2012.PubMed/NCBI
|
|
6
|
Terazawa T, Kondo S, Hosoi H, Morizane C,
Shimizu S, Mitsunaga S, Ikeda M, Ueno H and Okusaka T:
Transarterial infusion chemotherapy with cisplatin plus S-1 for
hepatocellular carcinoma treatment: A phase I trial. BMC Cancer.
14:3012014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang L, Zhang Q, Ren H, Ma S, Lu C, Liu
B, Liu J, Liang J, Li M and Zhu R: Dihydromyricetin enhances the
chemo-sensitivity of nedaplatin via regulation of the p53/Bcl-2
pathway in hepatocellular carcinoma cells. PLoS One.
10:e01249942015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu CY, Wu PT, Wang JP, Fan PW, Hsieh CH,
Su CL, Chiu CC, Yao CF and Fang K: An indolylquinoline derivative
promotes apoptosis in human lung cancer cells by impairing
mitochondrial functions. Apoptosis. 20:1471–1482. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee WY, Cheung CC, Liu KW, Fung KP, Wong
J, Lai PB and Yeung JH: Cytotoxic effects of tanshinones from
Salvia miltior-rhiza on doxorubicin-resistant human liver cancer
cells. J Nat Prod. 73:854–859. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gauthier A and Ho M: Role of sorafenib in
the treatment of advanced hepatocellular carcinoma: An update.
Hepatol Res. 43:147–154. 2013. View Article : Google Scholar
|
|
11
|
Hartmann JT and Kanz L: Sunitinib and
periodic hair depigmentation due to temporary c-KIT inhibition.
Arch Dermatol. 144:1525–1526. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sukowati CH, Rosso N, Crocè LS and
Tiribelli C: Hepatic cancer stem cells and drug resistance:
Relevance in targeted therapies for hepatocellular carcinoma. World
J Hepatol. 2:114–126. 2010.PubMed/NCBI
|
|
13
|
Banin S, Moyal L, Shieh S, Taya Y,
Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y,
et al: Enhanced phosphorylation of p53 by ATM in response to DNA
damage. Science. 281:1674–1677. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hamer G, Roepers-Gajadien HL, van
Duyn-Goedhart A, Gademan IS, Kal HB, van Buul PP and de Rooij DG:
DNA double-strand breaks and gamma-H2AX signaling in the testis.
Biol Reprod. 68:628–634. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuan J and Chen J: MRE11-RAD50-NBS1
complex dictates DNA repair independent of H2AX. J Biol Chem.
285:1097–1104. 2010. View Article : Google Scholar :
|
|
16
|
Di Leonardo A, Linke SP, Clarkin K and
Wahl GM: DNA damage triggers a prolonged p53-dependent G1 arrest
and long-term induction of Cip1 in normal human fibroblasts. Genes
Dev. 8:2540–2551. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Agarwal ML, Agarwal A, Taylor WR and Stark
GR: p53 controls both the G2/M and the G1 cell cycle checkpoints
and mediates reversible growth arrest in human fibroblasts. Proc
Natl Acad Sci USA. 92:8493–8497. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Innocente SA, Abrahamson JL, Cogswell JP
and Lee JM: p53 regulates a G2 checkpoint through cyclin B1. Proc
Natl Acad Sci USA. 96:2147–2152. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lakin ND and Jackson SP: Regulation of p53
in response to DNA damage. Oncogene. 18:7644–7655. 1999. View Article : Google Scholar
|
|
20
|
Assunção Guimarães C and Linden R:
Programmed cell deaths. Apoptosis and alternative death styles. Eur
J Biochem. 271:1638–1650. 2004. View Article : Google Scholar
|
|
21
|
Shi A, Nguyen TA, Battina SK, Rana S,
Takemoto DJ, Chiang PK and Hua DH: Synthesis and anti-breast cancer
activities of substituted quinolines. Bioorg Med Chem Lett.
18:3364–3368. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ding Y and Nguyen TA: PQ1, a quinoline
derivative, induces apoptosis in T47D breast cancer cells through
activation of caspase-8 and caspase-9. Apoptosis. 18:1071–1082.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bernzweig J, Heiniger B, Prasain K, Lu J,
Hua DH and Nguyen TA: Anti-breast cancer agents, quinolines,
targeting gap junction. Med Chem. 7:448–453. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakamura Y, Yogosawa S, Izutani Y,
Watanabe H, Otsuji E and Sakai T: A combination of indol-3-carbinol
and genistein synergistically induces apoptosis in human colon
cancer HT-29 cells by inhibiting Akt phosphorylation and
progression of autophagy. Mol Cancer. 8:1002009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chakrabarti G, Basu A, Manna PP, Mahato
SB, Mandal NB and Bandyopadhyay S: Indolylquinoline derivatives are
cytotoxic to Leishmania donovani promastigotes and amastigotes in
vitro and are effective in treating murine visceral leishmaniasis.
J Antimicrob Chemother. 43:359–366. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pal C, Raha M, Basu A, Roy KC, Gupta A,
Ghosh M, Sahu NP, Banerjee S, Mandal NB and Bandyopadhyay S:
Combination therapy with indolylquinoline derivative and sodium
antimony gluconate cures established visceral leishmaniasis in
hamsters. Antimicrob Agents Chemother. 46:259–261. 2002. View Article : Google Scholar
|
|
27
|
Brambilla E and Negoescu A: Analysis of
Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin
Cancer Res. 3:2181–2183. 1997.
|
|
28
|
Vaseva AV and Moll UM: The mitochondrial
p53 pathway. Biochimica et Biophysica Acta. 1787:414–420. 2009.
View Article : Google Scholar
|
|
29
|
Baker SJ, Fearon ER, Nigro JM, Hamilton
SR, Preisinger AC, Jessup JM, vanTuinen P, Ledbetter DH, Barker DF,
Nakamura Y, et al: Chromosome 17 deletions and p53 gene mutations
in colorectal carcinomas. Science. 244:217–221. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Linke SP, Clarkin KC, Di Leonardo A, Tsou
A and Wahl GM: A reversible, p53-dependent
G0/G1 cell cycle arrest induced by
ribo-nucleotide depletion in the absence of detectable DNA damage.
Genes Dev. 10:934–947. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Saha S, Bhattacharjee P, Mukherjee S,
Mazumdar M, Chakraborty S, Khurana A, Nayak D, Manchanda R,
Chakrabarty R, Das T, et al: Contribution of the ROS-p53 feedback
loop in thuja-induced apoptosis of mammary epithelial carcinoma
cells. Oncol Rep. 31:1589–1598. 2014.PubMed/NCBI
|
|
32
|
Macip S, Igarashi M, Berggren P, Yu J, Lee
SW and Aaronson SA: Influence of induced reactive oxygen species in
p53-mediated cell fate decisions. Mol Cell Biol. 23:8576–8585.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Raha S and Robinson BH: Mitochondria,
oxygen free radicals, disease and ageing. Trends Biochem Sci.
25:502–508. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Holley AK and St Clair DK: Watching the
watcher: Regulation of p53 by mitochondria. Future Oncol.
5:117–130. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mihara M, Erster S, Zaika A, Petrenko O,
Chittenden T, Pancoska P and Moll UM: p53 has a direct apoptogenic
role at the mitochondria. Mol Cell. 11:577–590. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ji H, Ding Z, Hawke D, Xing D, Jiang BH,
Mills GB and Lu Z: AKT-dependent phosphorylation of Niban regulates
nucleo-phosmin- and MDM2-mediated p53 stability and cell apoptosis.
EMBO Rep. 13:554–560. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Qian J, Zou Y, Rahman JS, Lu B and Massion
PP: Synergy between phosphatidylinositol 3-kinase/Akt pathway and
Bcl-xL in the control of apoptosis in adenocarcinoma cells of the
lung. Mol Cancer Ther. 8:101–109. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Malki A and El Ashry S: In vitro and in
vivo efficacy of a novel quinuclidinone derivative against breast
cancer. Anticancer Res. 34:1367–1376. 2014.PubMed/NCBI
|
